InsiderTrades

Form 4 for MBX MBX Biosciences, Inc.

Accepted 2024-09-17 00:00:00 ET · period of report 2024-09-16 · accession 0000950170-24-107489 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-09-17 2024-09-16 MBX Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 10% C - Cnv Deriv — +1.79M 1.79M New —
DM 2024-09-17 2024-09-16 MBX Wellington Biomedical Innovation Master Investors (Cayman) II L.P. 10% C - Cnv Deriv $0.00 -21.52M 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-09-16 C A 1,386,335 — 1,386,335 D — — (F1) Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date.
2 Common Common Stock 2024-09-16 C A 403,787 — 1,790,122 D — — (F2) Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date.
3 Derivative Series C Preferred Stock 2024-09-16 C D 4,854,368 $0.00 0 D — · — to — 403,787 Common Stock (F2) Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date.
4 Derivative Series B Preferred Stock 2024-09-16 C D 16,666,666 $0.00 0 D — · — to — 1,386,335 Common Stock (F1) Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date.